What changed
$AZN — ADD 📊 | 6 MONTHS THESIS
🎯 latest | Rev $2.7B | EPS $1.29 vs $1.27 🟢
💡 Consensus expects mid-single-digit revenue growth, but we see upside from key drugs like Tagrisso, Imfinzi, and emerging pipeline assets. Margin expansion is underappreciated, and upcoming trial readouts could accelerate sentiment.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 8/10 - Strong R&D and diversified portfolio, though patent cliffs and regulatory risks remain.
📊 Valuation: Fair to slightly rich: forward P/E ~17x vs peer median 15x, but premium justified by superior growth. EV/EBITDA ~13x vs 12x sector.
🔮 Catalyst: ESMO conference data presentation for key assets
💰 Entry: $176.72, stop $165, target $200
⚖️ Add AZN into portfolio weakness with a stop at $165, targeting $200 as pipeline catalysts and margin improvement drive re-rating.
📊 Our read: ADD. Full analysis →
https://stockduty.xyz/s/AZN0615